EMEA-003002-PIP03-22
Submitted by Anonymous (not verified) on 22 October 2025 - 10:33
EMEA-003002-PIP03-22
PSUSA/00000420/202411
Submitted by Anonymous (not verified) on 22 October 2025 - 10:29
PSUSA/00000420/202411
EMEA-000439-PIP03-23
Submitted by Anonymous (not verified) on 22 October 2025 - 9:23
EMEA-000439-PIP03-23
Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (24 September 2025)
Submitted by Anonymous (not verified) on 22 October 2025 - 9:19
Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) (24 September 2025)
Medicinal products for human use: monthly figures - September 2025
Submitted by Anonymous (not verified) on 22 October 2025 - 9:15
Medicinal products for human use: monthly figures - September 2025
Development of new medicinal products for the treatment of ulcerative colitis - Scientific guideline
Submitted by Anonymous (not verified) on 22 October 2025 - 8:20
Development of new medicinal products for the treatment of ulcerative colitis - Scientific guideline
EMEA-003526-PIP01-23
Submitted by Anonymous (not verified) on 21 October 2025 - 16:48
EMEA-003526-PIP01-23
EMEA-003089-PIP02-23
Submitted by Anonymous (not verified) on 21 October 2025 - 16:37
EMEA-003089-PIP02-23
EMEA-003495-PIP02-24
Submitted by Anonymous (not verified) on 21 October 2025 - 16:37
EMEA-003495-PIP02-24
Opinion/decision on a Paediatric investigation plan (PIP): Agamree, vamorolone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0355/2024
Submitted by Anonymous (not verified) on 21 October 2025 - 16:34
Opinion/decision on a Paediatric investigation plan (PIP): Agamree, vamorolone, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Congenital, familial and genetic disorders, PIP number: P/0355/2024